Where next for BTKi – BCL2i combinations in mantle cell lymphoma?
British Journal of Haematology · 2026-08 · 209 (2) · 853-854
DOI: 10.1111/bjh.70621 ↗Kurz gefasst
Kommentar in der Zeitschrift British Journal of Haematology, online erschienen am 14.06.2026. Verfasst von Toby A Eyre. Beteiligte Einrichtung: Churchill Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Proto-Oncogene Proteins c-bcl-2, Agammaglobulinaemia Tyrosine Kinase, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Commentary on: Wang et al. Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study. Br J Haematol 2026; 209(2): 734–739.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Churchill Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
ORCID-Profile: Toby A Eyre
Zitieren
APA
Eyre, T. A. (2026). Where next for BTKi – BCL2i combinations in mantle cell lymphoma?. British Journal of Haematology, 209(2), 853-854. https://doi.org/10.1111/bjh.70621
Vancouver
Eyre TA. Where next for BTKi – BCL2i combinations in mantle cell lymphoma?. British Journal of Haematology. 2026;209(2):853-854. doi:10.1111/bjh.70621
BibTeX
@article{Eyre2026,
author = {Eyre, Toby A},
title = {Where next for BTKi – BCL2i combinations in mantle cell lymphoma?},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {2},
pages = {853--854},
doi = {10.1111/bjh.70621}
}
EUVIMED